Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CVL 871

Next Previous
X
Search
Drug Profile

CVL 871

Alternative Names: CVL-871

Latest Information Update: 29 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics
  • Class Antidementias; Neuropsychotherapeutics
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dementia

Most Recent Events

  • 29 Apr 2022 Cerevel Therapeutics has patents pending for CVL 871 in United States and foreign jurisdictions prior to December 2021
  • 31 Dec 2021 Cerevel Therapeutics has patent protection for CVL 871 in United States, foreign jurisdictions, including Canada, Japan, China and various member states of the European Patent Office prior to December 2021
  • 22 Jun 2021 Phase-II clinical trials in Dementia in Canada, prior to March 2022 (PO) (NCT04958031)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top